Lumbago patient: role and place of B group vitamins


DOI: https://dx.doi.org/10.18565/therapy.2019.8.131-138

Pilipovich A.A., Danilov Al.B.

I.M. Sechenov First Moscow state medical university» of the Ministry of Healthcare of Russia (Sechenov University)
Article discusses modern conceptions about lumbar pains etiopathogenesis, relevant methods for the diagnosis and treatment of this group of diseases. A significant role in the complex treatment of dorsalgias by combined preparations of B group vitamins (thiamine + pyridoxine + cyanocobalamin) is noted, which, according to numerous studies with other drug groups use, improves the clinical effectiveness of the treatment and improves its tolerability.
Keywords: lumbar pain, discogenic pain, group B vitamins
Read entire article

Literature


  1. Hoy D. et al. A systematic review of the global prevalence of low back pain. Arthritis and rheumatism. 2012; 64: 2028–37.

  2. Vos T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study. Lancet. 2016; 390: 1211–59.

  3. Walker B.F. The prevalence of low back pain: a systematic review of the literature from 1966 to 1998. J Spinal Disord. 2000; 13: 205–17.

  4. Hoy D., Brooks P., Blyth F., Buchbinder R. The Epidemiology of low back pain. Best practice & research. Clinical rheumatology. 2010; 24: 769–81.

  5. van Tulder M., Becker A., Bekkering T., Breen A. et al. Chapter 3. European guidelines for the management of acute nonspecific low back pain in primary care. European spine journal: official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2006; 15 (Suppl 2): 169–91.

  6. Koes B.W., van Tulder M.W., Thomas S. Diagnosis and treatment of low back pain. BMJ. 2006; 332: 1430–34.

  7. Lewis J., O’Sullivan P. Is it time to reframe how we care for people with non-traumatic musculoskeletal pain? Br. J. Sports Med. 2018; 52 (24): 1543–44.

  8. Coste J., Delecoeuillerie G., Cohen de Lara A., Le Parc J.M., P Gurcay E., Bal A., Eksioglu E., Hasturk A.E. et al. Acute low back pain clinical course and prognostic factors. Disabil Rehabil. 2009; 31(10): 840–45.

  9. Thomas E., Silman A.J., Croft P.R., Papageorgiou A.C., Jayson M.I., Macfarlane G.J., Jones G.T., Johnson R.E., Wiles N.J., Chaddock C. et al. Predicting persistent disabling low back pain in general practice: prospective cohort study. Br J Gen Pract. 2006; 56(526): 334–41.

  10. Tsuji T., Matsudaira K., Sato H., Vietri J. The impact of depression among chronic low back pain patients in Japan. BMC Musculoskeletal Disorder. 2016; 17: 1–9.

  11. Deardorff W.W. Depression and chronic back pain. 2016; [October 14]. Available from: www.spine-health.com/condition/depression/depression-and-chronic-back-pain.

  12. Namgwa K.J., Terkura A., William Y., Daniel M.D., Cornilius E.I. Depression in patients with chronic low back pain: a hospital based study. Niger J Surg Res.2016; 17: 1–4.

  13. Sagheer M.A., Khan M.F., Sharif S. Association between chronic low back pain anxiety and depression in patients at a tertiary care centre. J Pak Med Assoc. 2013; 63: 688–90.

  14. Riely J.L. III, King C. Self report of alcohol use for pain in a multi-ethnic community sample. Journal of Pain. 2009; 10: 944–52.

  15. Bruehi S., Chung O.Y., Jirjis J.N., Biridepalli S. Prevalence of clinical hypertension in-patient with chronic pain compared to non pain general medical patients. Clin.J Pain. 2005; 21(2): 147–53.

  16. Omoke N.I., Igwe M.N. Analysis of risk factors for depression among patients with chronic low back pain in an orthopaedic clinic of a Nigerian teaching hospital. Afr Health Sci. 2019; 19(1): 1727–35.

  17. Moseley G.L., Butler D.S. Fifteen years of explaining pain: the past, present, and future. J Pain. 2015; 16: 807–13.

  18. Nijs J., Van Houdenhove B., Oostendorp R.A.B. Recognition of central sensitization in patients with musculoskeletal pain: application of pain neurophysiology in manual therapy practice. Man Ther. 2010; 15: 135–41.

  19. Neblett R., Cohen H., Choi Y., Hartzell M.M., Williams M., Mayer T.G., Gatchel R.J. The central sensitization inventory (CSI): Establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain. 2013; 14: 438–45.

  20. Nijs J., Apeldoorn A., Hallegraeff H., Clark J., Smeets R., Malfliet A., Girbes E.L., De Kooning M., Ickmans K. Low back pain: Guidelines for the clinical classification of predominant neuropathic, nociceptive, or central sensitization pain. Pain Physician 2015; 18: E333–E346.

  21. Clark J., Nijs J., Yeowell G., Goodwin P.C. What are the predictors of altered central pain modulation in chronic musculoskeletal pain populations? A systematic review. Pain Physician 2017; 20: 487–500.

  22. Clark J.R., Nijs J., Smart K., Holmes P., Yeowell G., Goodwin P.C. Prevalence of extreme trait sensory profiles and personality types in nonspecific chronic low back pain with predominant central sensitization: secondary analysis of an international observational study. Pain Physician. 2019; 22(3): E181–E190.

  23. Zehra U., Bow C., Lotz J.C. et al. Structural vertebral endplate nomenclature and etiology: a study by the ISSLS Spinal Phenotype Focus Group. Eur Spine J. 2018; 27(1): 2–12.

  24. DePalma M.J., Ketchum J.M., Saullo T. What is the source of chronic low back pain and does age play a role? Pain Med. 2011; 12 (2): 224–33.

  25. Arguisuelas M.D., Lison J.F., Sanchez‐Zuriaga D., Martinez‐Hurtado I., Domenech‐Fernandez J. Effects of myofascial release in nonspecific chronic low back pain: a randomized clinical trial. Spine (Phila Pa 1976). 2017; 42 (9):627–34.

  26. Langevin H.M., Fox J.R., Koptiuch C. et al. Reduced thoracolumbar fascia shear strain in human chronic low back pain. BMC Musculoskelet Disord. 2011; 12: 203.

  27. Teraguchi M., Samartzis D., Hashizume H. et al.Classification of high intensity zones of the lumbar spine and their association with other spinal MRI phenotypes: the Wakayama Spine Study. PLoS ONE. 2016; 11 (9): e0160111–6.

  28. Mosley G.E., Evashwick‐Rogler T.W., Lai A., Iatridis J.C. Looking beyond the intervertebral disc: the need for behavioral assays in models of discogenic pain. Ann N Y Acad Sci. 2017; 1409 (1): 51–66.

  29. Luk K.D., Samartzis D. Intervertebral disc «dysgeneration». Spine J. 2015; 15(9): 1915–18.

  30. Silagi E.S., Shapiro I.M., Risbud M.V. Glycosaminoglycan synthesis in the nucleus pulposus: dysregulation and the pathogenesis of disc degeneration. Matrix Biol. 2018; 71–72: 368–79.

  31. Dowdell J., Erwin M., Choma T., Vaccaro A., Iatridis J., Cho S.K. Intervertebral disk degeneration and repair.Neurosurgery. 2017; 80(3S): 46–54.

  32. Freemont A.J. The cellular pathobiology of the degenerate intervertebral disc and discogenic back Pain. Rheumatology (Oxford). 2009; 1: 5–10.

  33. Fujii K., Yamazaki M., Kang J.D., Risbud M.V., Cho S.K., Qureshi S.A., Hecht A.C., Iatridis J.C.. Discogenic back pain: literature review of definition, diagnosis, and treatment. JBMR Plus. 2019; 3(5): e10180.

  34. Carragee E.J., Don A.S., Hurwitz E.L. et al. 2009 ISSLS prize winner: does discography cause accelerated progression of degeneration changes in the lumbar disc: a ten‐year matched cohort study. Spine. 2009; 34 (21): 2338–45.

  35. Khan A.N., Jacobsen H.E., Khan J. et al. Inflammatory biomarkers of low back pain and disc degeneration: a review. Ann N Y Acad Sci. 2017; 1410 (1): 68–84.

  36. Grad S., Bow C., Karppinen J. et al. Systemic blood plasma CCL5 and CXCL6: potential biomarkers for human lumbar disc degeneration. Eur Cell Mater. 2016; 31: 1–10.

  37. de Queiroz B.Z., Pereira D.S., Lopes R.A. et al. Association between the plasma levels of mediators of inflammation with pain and disability in the elderly with acute low back pain: data from the Back Complaints in the Elders (BACE)-Brazil Study. Spine (Phila Pa 1976). 2016; 41 (3): 197–203.

  38. Zhang Y.G., Jiang R.Q., Guo T.-M., Wu S.X., Ma W.J. MALDI-TOF-MS serum protein profiling for developing diagnostic models and identifying serum markers for discogenic low back pain. BMC Musculoskelet Disord. 2014; 15: 193.

  39. Malik K.M., Cohen S.P., Walega D.R., Benzon H.T. Diagnostic criteria and treatment of discogenic pain: a systematic review of recent clinical literature. Spine J. 2013; 13(11): 1675–89.

  40. Данилов А.Б. Нейропатическая боль. Избранные лекции по неврологии. Под ред. Голубева В.Л. 2006; 203–223.

  41. Пилипович А.А. Боль в спине: подбор терапии с точки зрения безопасности и эффективности. Consilium Medicum. 2017; 19 (2.3. Неврология и Ревматология): 56–62.

  42. Данилов А.Б., Данилов Ал.Б. Управляй болью. Биопсихосоциальный подход. М. 2012. АММ ПРЕСС. С. 582.

  43. Mauro G.L., Martorana U., Cataldo P. et al. Vitamin B12 in low back pain: a randomised, double-blind, placebo-controlled study. Eur Rev Med Pharmacol Sci. 2000; 4(3): 53–58.

  44. Chiu C.K., Low T.H., Tey Y.S. et al. The efficacy and safety of intramuscular injections of methylcobalamin in patients with chronic nonspecific low back pain: a randomised controlled trial. Singapore Med J. 2011; 52(12): 868–73.

  45. Bruggemann G., Koehler C.O., Koch E.M. Results of a double-blind study of diclofenac + vitamin B1, B6, B12 versus diclofenac in patients with acute pain of the lumbar vertebre. A multicenter study. Klein Wochenschr. 1990; 2: 116–20.

  46. Kulwein A., Meyer H.J., Koehler C.O. Reduced diclofenac administration by B vitamins: results of a randomized double-blined study with reduced daily doses of diclofenac (75 mg diclofenac versus 75 mg diclofenac plus B vitamins) in acute lumbar vertebral syndromes. Klein Wochenschr. 1990; 2: 107–15.

  47. Старчина Ю.А. Витамины группы B в лечении заболеваний нервной системы. Неврология, нейропсихиатрия, психосоматика. 2009; 2: 84–87.


About the Autors

Anna Al. Pilipovich, PhD, associate professor of the Department of nervous diseases of Institute of professional education of I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia. Address: 119991, Moscow, 8/2 Trubetskaya Str. Tel.: +7 (495) 609-14-00. E-mail: aapilipovich@mail.ru
Alexey B. Danilov, MD, professor, head of the Department of nervous diseases of Institute of professional education of I.M. Sechenov First Moscow State medical University of the Ministry of Healthcare of Russia. Address: 119991, Moscow, 2/4 Bolshaya Pirogovskaya Str. Tel.: +7 (495) 609-14-00. E-mail: nervkafedra@gmail.com

Back to Content

Бионика Медиа